Search results for "CROHN DISEASE"

showing 10 items of 196 documents

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

2006

1. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Operative Unit of Gastroenterology, St Camillo-Forlanini Hospital, Rome, Italy. prantera@tin.it BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. AIM: To evaluate the difference in efficacy between once and twice/daily oral administration of rifaximin and placebo in the treatment of active Crohn's …

AdultMalemedicine.medical_specialtyPlacebo-controlled studyCIPROFLOXACINPlaceboGastroenterologyInflammatory bowel diseaseDrug Administration ScheduleRifaximinPlaceboschemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodIntestinal mucosaINFLAMMATORY-BOWEL-DISEASE C-REACTIVE PROTEIN ULCERATIVE-COLITIS METRONIDAZOLE CIPROFLOXACIN MANAGEMENT RECURRENCE DIARRHEA ANTIBODY MODERATEInternal medicinemedicineMANAGEMENTHumansPharmacology (medical)RECURRENCEAntibacterial agentCrohn's diseaseChi-Square DistributionHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.diseaseRifamycinsUlcerative colitisDIARRHEAC-REACTIVE PROTEINAnti-Bacterial AgentsSurgeryRifaximinTreatment OutcomechemistryULCERATIVE-COLITISANTIBODYMETRONIDAZOLEAcute Diseaserifaximin.crohn's diseaseMODERATEFemalebusinessINFLAMMATORY-BOWEL-DISEASE
researchProduct

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

2012

International audience; BACKGROUND: It remains to be shown whether inflammatory bowel disease (IBD) is associated with an increased risk of primary intestinal lymphoproliferative disorders (PILD). We assessed this risk in the CESAME French nationwide prospective observational cohort. METHODS: In all, 680 gastroenterologists enrolled 19,486 patients with IBD (Crohn's disease in 60.3%) from May 2004 to June 2005. Follow-up ended on 31 December 2007. Available biopsy samples and surgical specimens from patients with PILD (n = 14) were centralized for review. The reference incidence of PILD in the general population was obtained from the Côte d'Or registry and was used as a comparator to assess…

AdultMalemedicine.medical_specialtyPopulationGastroenterologyInflammatory bowel diseaseYoung Adult03 medical and health sciences0302 clinical medicineCrohn DiseaseInterquartile range[ CHIM.ORGA ] Chemical Sciences/Organic chemistryInternal medicineAzathioprinemedicineHumansImmunology and AllergyProspective StudiesChildeducationAgedAged 80 and overeducation.field_of_studyCrohn's diseaseThiopurine methyltransferasebiologyMercaptopurinebusiness.industry[CHIM.ORGA]Chemical Sciences/Organic chemistryIncidenceIncidence (epidemiology)GastroenterologyCase-control studyOdds ratioMiddle Agedmedicine.diseaseLymphoproliferative Disorders3. Good healthTreatment OutcomeCase-Control Studies030220 oncology & carcinogenesisbiology.proteinColitis UlcerativeFemale030211 gastroenterology & hepatologyFrancebusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

MR imaging of perianal fistulas in Crohn's disease: Sensitivity and specificity of STIR sequences

2015

Introduction Although some studies proved the role of STIR sequences in the evaluation of perianal fistulas in Crohn's Disease (CD), contrast medium is still injected in many institutions since there is not a validated reference MR protocol. Our purpose was to evaluate the role of the STIR sequence in the detection and characterization of perianal fistulae comparing it to the post-contrast T1 sequence and correlating it with rectal examination under anesthesia. Materials and methods We retrospectively reviewed all clinical records of 31 CD patients, suspected of having perianal fistulas, who had been submitted to an MR study before and after contrast medium injection and surgical exploratio…

AdultMalemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingFistulaCrohn's DiseaseInflammatory bowel diseaseInflammatory bowel disease030218 nuclear medicine & medical imaging03 medical and health sciencesYoung Adult0302 clinical medicineCrohn DiseaseRetrospective StudieMedicineHumansRectal FistulaNeuroradiologyRetrospective StudiesCrohn's diseasemedicine.diagnostic_testbusiness.industryMedicine (all)Magnetic resonance imagingInterventional radiologyGeneral MedicineRectal examinationSTIRMiddle Agedmedicine.diseaseMagnetic Resonance ImagingContrast medium030211 gastroenterology & hepatologyFemaleRadiologybusinessHuman
researchProduct

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

2017

AIM To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular and gastrointestinal activity, as well patient reported outcomes (PROs) of the HRQoL questionnaires. After this integrated evaluation and following a specific working flowchart, the Ada anti-tumor necrosis factor (TNF)-inhibitor was assigned to a cohort of 30 patients and its clinical efficacy was …

AdultMalemedicine.medical_specialtyTime FactorsTumor necrosis factor-inhibitorMultidisciplinary studyObservational StudyInflammatory bowel diseasesInflammatory bowel diseaseWorkflowEnteropathic spondyloarthriti03 medical and health sciences0302 clinical medicineCrohn DiseaseClinimetric assessmentInternal medicineSpondylarthritisTumor necrosis factor-inhibitorsAdalimumabHumansMedicinePatient Reported Outcome MeasuresPatient reported outcomes030203 arthritis & rheumatologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionAdalimumabGastroenterologyInflammatory Bowel DiseasesGeneral MedicineMiddle AgedPatient reported outcomeEnteropathic spondyloarthritisClinimetric assessment; Enteropathic spondyloarthritis; Inflammatory bowel diseases; Multidisciplinary evaluation; Patient reported outcomes; Tumor necrosis factor-inhibitors; GastroenterologyTreatment OutcomeMultidisciplinary evaluationAntirheumatic AgentsCritical PathwaysQuality of LifeColitis UlcerativeFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

Crohn's disease and fatigue: constancy and co-variations of activity of the disease, depression, anxiety and subjective quality of life.

2010

International audience; Fatigue in Crohn's disease (CD) is considered as a consequence of the disease and its treatment. If research showed the impact of the activity of the disease on vitality, patients can express fatigue even if the disease is inactive. Sleep disturbances are now considered in inflammatory bowel disease (IBD) and they could be involved in fatigue. It is well-known that depression and anxiety occur in IBD: They involve sleep disturbances and asthenia. But neither factors have been assessed simultaneously from a longitudinal perspective. Fifty-two patients participated in this study. Fatigue (MFI), depression (HAD-D), anxiety (HAD-A), sleep disturbances (ISI, IQPS), subjec…

AdultMalemedicine.medical_specialty[SHS.PSY]Humanities and Social Sciences/PsychologyContext (language use)DiseaseAnxietyInflammatory bowel disease[SHS.PSY] Humanities and Social Sciences/Psychology03 medical and health sciences[ SHS.PSY ] Humanities and Social Sciences/Psychology0302 clinical medicineCrohn DiseaseQuality of life[ CHIM.ORGA ] Chemical Sciences/Organic chemistrySurveys and QuestionnairesInternal medicinemedicineHumansPsychiatryFatigueApplied PsychologyDepression (differential diagnoses)Crohn's diseaseDepression[CHIM.ORGA]Chemical Sciences/Organic chemistryMiddle Agedmedicine.diseasedigestive system diseases3. Good healthPsychiatry and Mental healthClinical PsychologySleep deprivationQuality of LifeSleep DeprivationAnxietyFemale030211 gastroenterology & hepatologymedicine.symptomPsychology030217 neurology & neurosurgery
researchProduct

Forty-slice MDCT enteroclysis: evaluation after oral administration of isotonic solution in Crohn's disease.

2007

Objective. The aim of this study was to evaluate the accuracy of multidetector computed tomography (MDCT) enteroclysis after oral hyperhydration with isotonic solution in detecting bowel wall alterations in patients with Crohn’s disease. Materials and methods. Twenty-eight patients with a diagnosis of Crohn’s disease established by ileocolonoscopy and histology were enrolled in the study; 15 patients with negative ileocolonoscopy served as controls. In all cases, MDCT enteroclysis was performed after oral administration of 2,000 ml of isotonic solution and intravenous administration of N-butylscopolamine. Axial, isotropic multiplanar and volume-rendered reconstructions were used to evaluate…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAdministration OralContrast MediaIntestino tenueSensitivity and SpecificityPolyethylene GlycolsCrohn DiseaseOral administrationPatologie gastrointestinaliIntestine SmallMedicineIntubationHumansRadiology Nuclear Medicine and imagingNeuroradiologyTC multidetettoreCrohn's diseasemedicine.diagnostic_testbusiness.industryCatharticsMultidetector CTUltrasoundInterventional radiologyGeneral MedicineEnemamedicine.diseaseGastrointestinal diseaseSmall boweldigestive system diseasesSpiral computed tomographyIopamidolFemaleRadiologyIsotonic SolutionsbusinessTomography X-Ray ComputedLa Radiologia medica
researchProduct

Crohn's disease: A comparative prospective study of transabdominal ultrasonography, small intestine contrast ultrasonography, and small bowel enema

2005

Background: Small intestine contrast ultrasonography (SICUS), when performed after distention of the small bowel lumen with an iso-osmolar polyethylene glycol electrolyte-balanced solution, shows high sensitivity (100%) and specificity (97%) in detecting small bowel abnormalities in patients who have not received a diagnosis but in whom there is a suspicion of intestinal diseases. The diagnostic yield of SICUS remains to be established in detecting small bowel lesions in patients with proven Crohn's disease (CD) in comparison with transabdominal ultrasonography (TUS), and in relationship to the experience of the operator, using small bowel enema (SBE) as the “gold standard.” Aim: The aim of…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentContrast MediaSmall bowel enemaLumen (anatomy)EnemaSensitivity and SpecificityGastroenterologyPolyethylene GlycolsDiagnosis DifferentialJejunumSettore MED/12Professional CompetenceCrohn DiseaseInternal medicineAbdomenIntestine SmallmedicineHumansImmunology and AllergyProspective cohort studyUltrasonographyCrohn's diseaseSicusbiologybusiness.industryGastroenterologyEnemaMiddle AgedSmall bowelmedicine.diseasebiology.organism_classificationSmall intestineCrohn's diseaseStenosismedicine.anatomical_structureSolventsFemalebusinessDilatation Pathologic
researchProduct

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1993

Abstract Background: The role of azathioprine (AZA) in the treatment of active Crohn's disease (CD) is still controversial. This study examined whether AZA combined with standard prednisolone therapy improved the therapeutic outcome compared with monotherapy with prednisolone. Methods: Forty-two patients with a Crohn's Disease Activity Index (CDAI) of > 150 were randomized into two groups. Both received 60 mg of prednisolone daily in a tapering regimen to a maintenance dose of 10 mg. In addition, group 1 received 2.5 mg AZA/kg body wt and group 2 received a placebo over the whole study period of 4 months. Results: At the end of the trial, 16 of 21 patients (76%) in group 1 were in remission…

Adultmedicine.medical_specialtyAdolescentPrednisolonemedicine.medical_treatmentAzathioprinePlaceboGastroenterologylaw.inventionCrohn DiseaseRandomized controlled triallawInternal medicineAzathioprinemedicineHumansChemotherapyHepatologybiologyMaintenance dosebusiness.industryC-reactive proteinGastroenterologyMiddle AgedSurgeryRegimenTreatment OutcomePrednisolonebiology.proteinDrug Therapy Combinationbusinessmedicine.drugGastroenterology
researchProduct

6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease.

2005

Background & Aims: Azathioprine is the gold standard for immunosuppressive therapy in Crohn's disease (CD) and its molecular mechanism of action is caused by the metabolite 6-thioguanosine triphosphate (TGTP). In this study we assessed the impact of TGTP levels for monitoring of azathioprine therapy. Methods: A novel, highly sensitive assay was established to measure levels of TGTP and its precursors 6-thioguanosine monophosphates and 6-thioguanosine diphosphates (TGDP) in red blood cells from 50 CD patients. The results were correlated with clinical outcome. Results: TGTP levels could be quantified in 47 patients and a subgroup of these patients showed significantly high levels of TGDP. 6-…

Adultmedicine.medical_specialtyErythrocytesMetaboliteAzathioprineInflammatory bowel diseaseGastroenterologyGuanosine Diphosphatechemistry.chemical_compoundCrohn DiseaseInternal medicineAzathioprinemedicineHumansCrohn's diseaseHepatologyThiopurine methyltransferasebiologybusiness.industryGastroenterologyAzathioprine therapyAntibodies MonoclonalThionucleotidesmedicine.diseaseInfliximabGuanine NucleotidesInfliximabRed blood cellmedicine.anatomical_structurechemistryImmunologybiology.proteinbusinessBiomarkersImmunosuppressive Agentsmedicine.drugClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct